DK1140148T3 - Lagerholdbar formulering af glucagon-agtigt peptid-1 - Google Patents

Lagerholdbar formulering af glucagon-agtigt peptid-1

Info

Publication number
DK1140148T3
DK1140148T3 DK99967463T DK99967463T DK1140148T3 DK 1140148 T3 DK1140148 T3 DK 1140148T3 DK 99967463 T DK99967463 T DK 99967463T DK 99967463 T DK99967463 T DK 99967463T DK 1140148 T3 DK1140148 T3 DK 1140148T3
Authority
DK
Denmark
Prior art keywords
glucagon
peptide
stable storage
storage formulation
glp
Prior art date
Application number
DK99967463T
Other languages
Danish (da)
English (en)
Inventor
Mark L Brader
Allen H Pekar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1140148T3 publication Critical patent/DK1140148T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
DK99967463T 1998-12-22 1999-12-21 Lagerholdbar formulering af glucagon-agtigt peptid-1 DK1140148T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11349998P 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
DK1140148T3 true DK1140148T3 (da) 2006-01-30

Family

ID=22349808

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99967463T DK1140148T3 (da) 1998-12-22 1999-12-21 Lagerholdbar formulering af glucagon-agtigt peptid-1

Country Status (9)

Country Link
EP (1) EP1140148B1 (ja)
JP (1) JP4689833B2 (ja)
AT (1) ATE307603T1 (ja)
AU (1) AU2373400A (ja)
CA (1) CA2358107C (ja)
DE (1) DE69928006T2 (ja)
DK (1) DK1140148T3 (ja)
ES (1) ES2249933T3 (ja)
WO (1) WO2000037098A1 (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
EP2062593A3 (en) 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
EP1412384B1 (en) * 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
CN1571676A (zh) 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
JP2007524592A (ja) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
ATE529126T1 (de) * 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
PL1633390T3 (pl) * 2003-06-03 2012-06-29 Novo Nordisk As Stabilizowane kompozycje farmaceutyczne peptydu glp-1
EP1687019B1 (en) 2003-11-20 2017-11-22 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
DE602005016952D1 (de) 2004-10-21 2009-11-12 Novo Nordisk As Wählmechanismus für einen drehstift
ES2575984T3 (es) * 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
ES2735533T3 (es) * 2004-11-12 2019-12-19 Novo Nordisk As Formulaciones estables de GLP-1
PL2209800T3 (pl) 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
EP2384338A4 (en) * 2008-12-29 2013-01-16 Panacea Biotec Ltd GLP-1 ANALOGS AND THEIR APPLICATIONS
WO2010138671A1 (en) 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
JP2014504588A (ja) 2010-12-22 2014-02-24 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
RU2014128518A (ru) 2011-12-29 2016-02-20 Ново Нордиск А/С Механизм увеличения/уменьшения дозы для взводимого шприца-ручки
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
SG11201805255TA (en) 2015-12-23 2018-07-30 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
WO2020208541A1 (en) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprising glp-1 analogue
US20220372072A1 (en) * 2019-09-19 2022-11-24 Dr. Reddy's Laboratories Limited Improved purification processes for liraglutide
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110083T1 (de) * 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
EP0796106B1 (en) * 1994-12-23 2003-03-19 Novo Nordisk A/S Protracted glp-1 compositions

Also Published As

Publication number Publication date
JP4689833B2 (ja) 2011-05-25
CA2358107A1 (en) 2000-06-29
AU2373400A (en) 2000-07-12
CA2358107C (en) 2011-08-23
DE69928006D1 (de) 2005-12-01
EP1140148A1 (en) 2001-10-10
ES2249933T3 (es) 2006-04-01
DE69928006T2 (de) 2006-07-13
ATE307603T1 (de) 2005-11-15
EP1140148B1 (en) 2005-10-26
WO2000037098A1 (en) 2000-06-29
JP2002532557A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
DK1140148T3 (da) Lagerholdbar formulering af glucagon-agtigt peptid-1
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
BG103800A (en) Method and composition for the treatment of apnoea
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
FI971277A0 (fi) IRDS:in ja ARDS:in hoitoon tarkoitettuja koostumuksia, jotka sisältävät ainakin yhtä glukortikosteroidia yhdistelmänä keuhkopinta-aktiivisen aineen kanssa
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
CA2260943A1 (en) Formulation of 5-ht agonists
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
AU1718400A (en) Method for treating pain
TW200626613A (en) Analogues of GLP-1
HK1054681A1 (en) Treatment of acute coronary syndrome with glp-1
PT1141014E (pt) Variante mutante do factor de crescimento semelhante a insulina (igf-i)
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
GB9806632D0 (en) Peptide factor
TR200202323T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavß6 antagonistleriyle tedavisi
WO2001034172A3 (en) Methods and compositions for treating reward deficiency syndrome
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
ES2133152T3 (es) Composicion de tiotepa liofilizada estable.
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
BG103543A (en) The use of pramipexol in the treatment of the uneasy legs syndrome
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
DE69929635D1 (de) Neue pharmazeutische zusammenstellung und deren herstellungsprozess
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner